论文部分内容阅读
本文目的为评价新的胰癌标记物CA242的诊断价值并与CA199、CA50、CEA作比较。 方法:1986年3月至1991年5月间采集300例手术前患者和30例健康对照者的血清,其中68例胰管癌,24例其他胰腺肿瘤,57例急性胰腺炎,29例慢性胰腺炎,90例有上消化道良性疾病,32例恶性病变,CA242测定用两步DELFIA三明治法,正常上限定为20U/ml,CA19-9上限为37U/ml,CA50上限为17U/ml,CEA上限为5ng/ml。 结果:胰癌患者的CA242值为0.2～119400U/ml,平均4360±16300U/ml,慢性胰腺炎22.5±35.5U/ml,胆石症13.1±13.1U/ml,正常人9.7±4.4U/ml,其他恶性肿瘤4321±12348U/ml。CA242、CA19-9及CA50对胰癌的敏感性相应为66.2％、70.6％及
This article aims to evaluate the diagnostic value of the novel pancreatic cancer marker CA242 and compare it with CA199, CA50, and CEA. METHODS: From March 1986 to May 1991, the serum of 300 pre-operative patients and 30 healthy controls were collected, including 68 pancreatic duct carcinomas, 24 other pancreatic tumors, 57 acute pancreatitis, and 29 chronic pancreatitis. Inflammation, 90 cases of benign diseases of the upper digestive tract, 32 cases of malignant lesions, CA242 determination using two-step DELFIA sandwich method, normally limited to 20U/ml, CA19-9 upper limit of 37U/ml, CA50 upper limit of 17U/ml, CEA The upper limit is 5 ng/ml. Results: The CA242 value of pancreatic cancer patients was 0.2-119400 U/ml, averaged 4360±16300 U/ml, chronic pancreatitis 22.5±35.5 U/ml, cholelithiasis 13.1±13.1 U/ml, normal person 9.7±4.4 U/ml, Other malignant tumors were 4321±12348 U/ml. The sensitivity of CA242, CA19-9 and CA50 to pancreatic cancer was 66.2% and 70.6% respectively.